Juan González‐García

Author

Also Known As

A González-Baeza, E. Valencia, F. Arnalich, Garcia, Juan Gonzalez, Hollie Saunders, Inmaculada Segarra, Inés Suárez‐García, J Garcia, J Gonzalez-García, J Gonzalez‐Garcia

288

Publications

7.4K

Citations

H-Index

Concepts

All Affiliations

Hospital Universitario La Paz Hospital General Universitario Gregorio Marañón Instituto de Salud Carlos III Hospital Universitario Ramón y Cajal Hospital Universitario Príncipe de Asturias

About

Juan González‐García is an author at Hospital Universitario La Paz specializing in medicine, hiv, and epidemiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	29	1.5K
2	Public Health	11	14	387
3	Health Sciences	4	4	74
4	Engineering	2	2	40
5	Anatomy	1	1	13

Juan González‐García

111

Publications

Citations

H-Index

Page 1

	Year	Citations
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV-Infected Patients Francesca J. Torriani, M. Rodríguez‐Torres, Jürgen K. Rockstroh, New England Journal of Medicine	2004	1.2K
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial David A. Margolis, Juan González‐García, Hans-Jürgen Stellbrink, The Lancet Treatment And PreventionMedicinePhase 2BLong-acting Intramuscular CabotegravirAntiviral Therapy	2017	492
Sustained virological response to interferon plus ribavirin reduces liver‐related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus† Juan Berenguer, J. Alvarez-Pellicer, Pilar Miralles Martín, Hepatology	2009	295
Severe Nucleoside-Associated Lactic Acidosis in Human Immunodeficiency Virus–Infected Patients: Report of 12 Cases and Review of the Literature Dolors Rodríguez-Pardo, Esteban Ribera, Estebán Martínez, Clinical Infectious Diseases Primary ImmunodeficiencyLactic AcidosisNeurovirologyImmunologyHiv Infection	2002	181
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study Chloe Orkin, Shinichi Oka, Patrick Philibert, The Lancet HIV Treatment And PreventionMedicineAntiviral Drug DevelopmentAntiviral TherapyPharmacotherapy	2021	166
Sustained Virological Response to Interferon Plus Ribavirin Reduces Non-Liver-Related Mortality in Patients Coinfected With HIV and Hepatitis C Virus Juan Berenguer, Elisa Boucourt Rodríguez, Pilar Miralles, Clinical Infectious Diseases	2012	159
Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV Federico Pulido, José Ramón Arribas, Rafaël Delgado, AIDS	2008	154
Lopinavir/Ritonavir as Single-Drug Therapy for Maintenance of HIV-1 Viral Suppression José Ramón Arribas, Federico Pulido, Rafaël Delgado, JAIDS Journal of Acquired Immune Deficiency Syndromes	2005	149
Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19) Jesús Rodríguez‐Baño, Jerónimo Pachón, Jordi Carratalà, Clinical Microbiology and Infection	2020	127
Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study Belén Gutiérrez‐Gutiérrez, María Dolores del Toro, Alberto M. Borobia, The Lancet Infectious Diseases Prognostic EvaluationDisease ProgressionMulticentre Cohort StudyClinical PhenotypesClinical Epidemiology	2021	98

Page 1